| Printable Copy |
 |
| Printable Copy |
|
Vaccine. 2016 Nov 22. pii: S0264-410X(16)31030-1. doi: 10.1016/j.vaccine.2016.10.078. [Epub ahead of print]
Vaccine strategies: Optimising outcomes.
Hardt K1 Bonanni P2 King S3 Santos JI4 El-Hodhod M5 Zimet GD6 Preiss S7.
Abstract
Successful immunisation programmes generally result from high vaccine effectiveness and adequate uptake of vaccines. In the development of new vaccination strategies the structure and strength of the local healthcare system is a key consideration. In high income countries existing infrastructures are usually used while in less developed countries the capacity for introducing new vaccines may need to be strengthened particularly for vaccines administered beyond early childhood such as the measles or human papillomavirus (HPV) vaccine. Reliable immunisation service funding is another important factor and low income countries often need external supplementary sources of finance. Many regions also obtain support in generating an evidence base for vaccination via initiatives created by organisations including World Health Organization (WHO) the Pan American Health Organization (PAHO) the Agence de Médecine Préventive and the Sabin Vaccine Institute. Strong monitoring and surveillance mechanisms are also required. An example is the efficient and low-cost approaches for measuring the impact of the hepatitis B control initiative and evaluating achievement of goals that have been established in the WHO Western Pacific region. A review of implementation strategies reveals differing degrees of success. For example in the Americas PAHO advanced a measles-mumps-rubella vaccine strategy targeting different population groups in mass catch-up and follow-up vaccination campaigns. This has had much success but coverage data from some parts of the region suggest that children are still not receiving all appropriate vaccines highlighting problems with local service infrastructures. Stark differences in coverage levels are also observed among high income countries as is the case with HPV vaccine implementation in the USA versus the UK and Australia reflecting differences in delivery settings. Experience and research have shown which vaccine strategies work well and the factors that encourage success which often include strong support from government and healthcare organisations as well as tailored culturally-appropriate local approaches to optimise outcomes.